Drug intelligence / Profile preview

Granisetron Hydrochloride Nasal Spray

Development stage: Unknown
Lead developer: Maxinase Life Sciences
Modality: Small Molecules
Administration: Intranasal

Overview

Granisetron Hydrochloride Nasal Spray (GNS) is a pharmaceutical formulation containing Granisetron Hydrochloride, a selective serotonin 5-HT3 receptor antagonist. It is designed for intranasal administration and is being studied for its pharmacokinetics, safety, and tolerability. Granisetron is an antiemetic primarily used to prevent nausea and vomiting, particularly that induced by chemotherapy or radiotherapy.

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on Granisetron Hydrochloride Nasal Spray.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granisetron Hydrochloride Nasal Spray.

Explore the full profile